Histidine-rich glycoprotein as a prognostic biomarker for sepsis.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Proteins/*metabolism ; Sepsis/*diagnosis ; Sepsis/*metabolism; Biomarkers/blood ; Enzyme-Linked Immunosorbent Assay/methods ; Glycoproteins/analysis ; Glycoproteins/blood ; Glycoproteins/metabolism ; Proteins/analysis ; Sepsis/mortality ; Aged ; Aged, 80 and over ; Female ; Humans ; Japan ; Male ; Middle Aged ; Prognosis ; Histidine-Rich Glycoprotein

Various biomarkers have been proposed for sepsis; however, only a few become the standard. We previously reported that plasma histidine-rich glycoprotein (HRG) levels decreased in septic mice, and supplemental infusion of HRG improved survival in mice model of sepsis. Moreover, our previous clinical study demonstrated that HRG levels in septic patients were lower than those in noninfective systemic inflammatory response syndrome patients, and it could be a biomarker for sepsis. In this study, we focused on septic patients and assessed the differences in HRG levels between the non-survivors and survivors. We studied ICU patients newly diagnosed with sepsis. Blood samples were collected within 24 h of ICU admission, and HRG levels were determined using an enzyme-linked immunosorbent assay. Ninety-nine septic patients from 11 institutes in Japan were included. HRG levels were significantly lower in non-survivors (n = 16) than in survivors (n = 83) (median, 15.1 [interquartile ranges, 12.7-16.6] vs. 30.6 [22.1-39.6] µg/ml; p < 0.01). Survival analysis revealed that HRG levels were associated with mortality (hazard ratio 0.79, p < 0.01), and the Harrell C-index (predictive power) for HRG was 0.90. These results suggested that HRG could be a novel prognostic biomarker for sepsis.

Virulence. 2014 Jan 1;5(1):154-60. (PMID: 24335467)
JAMA. 2016 Feb 23;315(8):801-10. (PMID: 26903338)
Crit Care Med. 2003 Apr;31(4):1250-6. (PMID: 12682500)
BMJ. 2007 Oct 20;335(7624):806-8. (PMID: 17947786)
Crit Care Med. 2009 May;37(5):1649-54. (PMID: 19325482)
Crit Care Med. 1998 Nov;26(11):1793-800. (PMID: 9824069)
Pharmacol Res Perspect. 2019 May 22;7(3):e00481. (PMID: 31143450)
PLoS One. 2015 Jun 15;10(6):e0129450. (PMID: 26076027)
Clin Infect Dis. 2014 Dec 15;59(12):1761-7. (PMID: 25228701)
Crit Care Med. 2018 Apr;46(4):570-576. (PMID: 29303798)
Blood. 2011 Feb 17;117(7):2093-101. (PMID: 20971949)
Ann Intensive Care. 2017 Sep 6;7(1):91. (PMID: 28875483)
Blood. 2010 Sep 30;116(13):2365-72. (PMID: 20587784)
Clin Rev Allergy Immunol. 2008 Jun;34(3):307-12. (PMID: 18219588)
Br J Pharmacol. 2019 Aug;176(15):2808-2824. (PMID: 31093964)
JAMA. 2017 Oct 3;318(13):1241-1249. (PMID: 28903154)
Intensive Care Med. 2018 Jul;44(7):1061-1070. (PMID: 29959455)
Biomed Res Int. 2014;2014:547818. (PMID: 24800240)
Crit Care. 2018 Aug 17;22(1):209. (PMID: 30119699)
Intensive Care Med. 2017 Mar;43(3):304-377. (PMID: 28101605)
Biomed Res Int. 2013;2013:258029. (PMID: 24175285)
PLoS One. 2018 Jan 24;13(1):e0191486. (PMID: 29364941)
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. (PMID: 26414292)
EBioMedicine. 2016 Jul;9:180-194. (PMID: 27333033)

0 (Biomarkers)
0 (Glycoproteins)
0 (Proteins)
0 (Histidine-Rich Glycoprotein)

Date Created: 20210514 Date Completed: 20211108 Latest Revision: 20250103

20260130

PMC8119687

10.1038/s41598-021-89555-z

33986340